HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives

A. AbdAllah

doi:10.1039/d5ra09034b

January 1, 2026RSC AdvancesOpen Access

HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to analyze clinical data on HDAC inhibitors to understand their effectiveness in cancer treatment.
Collected data from clinical trials involving HDAC inhibitors.
Compared various structural features of these compounds.
Analyzed the impact of those features on anticancer efficacy.
Identified key structural features that affect the efficacy of HDAC inhibitors.
Revealed limitations and challenges faced in clinical applications.
Suggested pathways for improving future cancer therapies using HDAC inhibitors.

Implication

Clinical data compare HDAC inhibitors' structural features to enhance anticancer therapies, suggesting new possibilities.

Abstract

In an attempt to collect clinical data about HDAC inhibitors as very significant anticancer drugs, we aimed to compare data and reveal the impact of the structural features to help – develop better cancer therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

A. AbdAllah (2026) studied this question.

synapsesocial.com/papers/696b25a9d2a12237a93490b2 https://doi.org/10.1039/d5ra09034b

View Full Paper

Ask AI

Bookmark

Share

HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives

Key Points

Implication

Abstract

Discussion

Cite This Study

HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading